2 future growth stocks I’d buy today

Can these cash-burn stocks of the present really turn into profit stars of the future?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Should you invest in companies that are not yet in profit? It can be very risky, but today I’m looking at a couple of candidates.

Science in Sport (LSE: SIS) is one that appeared on my radar last year when I took up cycling again after a long break, and how things had changed. Out were baggy ‘Famous Five’ shorts and sausage butties for lunch, and in were lycra and energy gels.

In fact, sports nutrition is becoming big business, and that’s what Science in Sport does. You can see it everywhere after a big sporting event like the Olympics, and sales of all kinds of gels, energy bars, and scientifically formulated hydration products (ie drinks) all soar.

The Tour de France helped, and when I see groups out cycling they’re all wearing team gear and slurping down those horrible gels — I tried one once and I thought it tasted of sick, but I’m not a target customer.

Sports everywhere

There’s the London Marathon too, with competitors trying to squeeze out every last smidgeon of performance they can.

Science in Sport doesn’t make any profit yet and still has losses (albeit narrower losses) pencilled in for the next two years. But on Friday it announced two new deals, a three-year one with USA Triathlon to target growth in the US market, and a partnership with Rock ‘n’ Roll Marathon Series to be the “official supplier of its patented isotonic energy gels at all 30 race series.

The risks are huge — market cap of only £27m and still in the cash-burn stage — so be very careful if you choose to make an investment. But with the shares at 72p, I’m cautiously optimistic.

Medical prospect

Shares in Circassia Pharmaceuticals (LSE: CIR) crashed in June 2016 when a cat allergy phase III study failed miserably — the candidate immunotherapy treatment did no better than a placebo.

Since then, the company has reinvented itself and now focuses on respiratory diseases, including asthma and COPD. Those are growing problems in the industrialised west, surely offering great potential for anyone coming up with effective treatments.

September’s interim results looked encouraging to me, reporting an increase in revenue of 65%, to £18.3m, with R&D expenditure upped to £27.2m. The latter is particularly exciting as it includes a £14.6m contribution to the firm’s collaboration with sector giant AstraZeneca. Announced in March, the deal secured certain US commercial rights to the COPD treatments Tudorza and Duaklir.

Sales of the firm’s NIOX asthma diagnostic product were up 19% at the halfway stage, with US clinical sales up 39%.

Sufficient cash

With £82.9m in cash at 30 June, there appear to be no liquidity problems at present, but questions over profits remain. There are none forecast for this year and next, though losses per share are forecast to fall sharply, so could we see some in 2019?

At 84p today, the shares have continued down, which is disappointing. And it is another very risk investment, as it doesn’t take much going wrong to destroy a company that’s not yet in profit.

But Neil Woodford has held on to his Circassia shares and clearly still sees something attractive there, and I’m with him. What I really want to see is full-year results for 2017, and the first signs of 2019 forecasts.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

How much passive income could a £20,000 ISA provide in a year?

A diversified portfolio of high-yield FTSE shares can build a large and reliable passive income over time, as Royston Wild…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

See how much an investor needs in an ISA to fund an £888 monthly passive income

Harvey Jones grabs his calculator to work out how much money people need to generate a decent passive income in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Value Shares

The BP share price is climbing – see how much £10k invested 1 month ago is worth now

It's been a tough few years for the BP share price. Harvey Jones examines whether the FTSE 100 oil giant…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock has soared 1,471% in 5 years. Here’s how I’m hunting for the next Nvidia!

Nvidia stock has put in a stunning performance over the past five years. This writer tries to apply some lessons…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

If someone decided to start buying shares with £10k a year ago, here’s what they could be sitting on now!

If someone had started buying shares a year ago with £10k, what might have happened? Our writer outlines some factors…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

The Rolls-Royce share price is close to an all-time record. Could it still be a bargain?

The Rolls-Royce share price has been punching out the lights of late. Our writer thinks things could get even better…

Read more »

4 Teslas in a parking lot at a charger station
Investing Articles

The Tesla share price slips further — how much would £10k invested at the start of the year be worth now?

The Tesla share price remains under pressure, with risks mounting from multiple directions. Here’s what a £10,000 investment would be…

Read more »

British pound data
Investing Articles

The Ocado share price is a sea of red! Time to cut my losses?

Every time Harvey Jones checks out the Ocado share price, he sees red. Will it ever stop falling and leaving…

Read more »